BMS company not required to pay damages in trade secrets case

12-11-2018

BMS company not required to pay damages in trade secrets case

Chris Ryan / iStockphoto.com

A jury has said that Flexus Biosciences, a company owned by Bristol-Myers Squibb (BMS), does not need to pay damages despite being liable for trade secrets misappropriation.


Bristol-Myers Squibb, Flexus Biosciences, Incyte, trade secrets misappropriation, jury trial, ICO-1, oncology, cancer research and development

LSIPR